<DOC>
	<DOCNO>NCT01785784</DOCNO>
	<brief_summary>This multicenter , randomize , phase Ⅳ study , investigate extensive efficacy safety Recombinant Human Granulocyte/Macrophage Colony-stimulating Factor Hydro-gel Topical Application ( rhGM-CSF Gel ) deep 2nd burn . There two part phase Ⅳstudy , first part multicenter , randomize , reference control study , subject randomize two group , test group ( rhGM-CSF Gel ) control group ( iodophor gauze ) , totally 358 deep 2nd burn patient enrol first part study , 177 case enrolled test group 181 case enrol reference control group . In test group , patient enrol group , clean wound surface regularly wash normal saline , spread test drug wound surface , bandage sterilize vaseline gauze , change drug product every two one day accord effusion . In reference control group , patient enrol group , clean wound surface regularly wash normal saline , bandage iodophor gauze , change drug product every two one day accord effusion . Whole treatment last till wound surface heal completely , recover 4 week , calculate record heal rate . The secondary part study multicenter , open study , investigate safety rhGM-CSF deep 2nd burn patient . Totally 2329 patient enrol part study .</brief_summary>
	<brief_title>Efficacy Safety Study rhGM-CSF Gel Treat Deep 2nd Thickness Burn</brief_title>
	<detailed_description />
	<mesh_term>Burns</mesh_term>
	<criteria>age le 3 year old , gender ok. subject diagnose deep 2nd thickness burn subject administrate topical durg wind surface enrol clinical study . subject sign &lt; inform consent &gt; age less 3 year old subject participate clinical trial within 3 month subject administrated topical drug wind surface enrol clinical study female subject lactation pregnancy subject allergic rhGMCSF , allergic history many drug product allergic disease recently subject serious heart disease , unstable angina pectoris break , cardiac functional insufficiency , myocardial infarction serious general infection . subject serious renal inadequacy , creatinine ( Cr ) 2.5 time upper limit aspartate aminotransferase alanine transpeptidase 2.5 time upper limit subject use immunosuppressant</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2013</verification_date>
</DOC>